Upstream Bio
PublicUpstream Bio is now publicly traded
The data on this page reflects Upstream Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Jun 8, 2023
Total Funding Raised
$200M
Company Overview
Upstream Bio operates in Biotech and is based in Waltham, Massachusetts. It has raised $200M.
Upstream Bio is a biotechnology company focused on developing innovative therapeutics for allergic and inflammatory diseases through its clinical-stage monoclonal antibody targeting the TSLP receptor.
Sector
Biotech
AI Layer
Non-AI
Upstream Bio Comparables
Compare Upstream Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GSK plc | 82% | |
| Evommune | 59% | |
| Aer Therapeutics | 53% |
For institutional investors. Book with your work email.
Upstream Bio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Upstream Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Enavate Sciences | Series B |
| Bain Capital Life Sciences | Series B |
| TCG Crossover | Series B |
| Omega Funds | Series B |
| Altshuler Shaham Provident Funds and Pension Ltd. | Series B |
| OrbiMed | Series B |
| HBM Healthcare Investments | Series B |
For institutional investors. Book with your work email.
Upstream Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.